Please login to the form below
medicines value
This page shows the latest medicines value news and features for those working in and with pharma, biotech and healthcare.
Who's calling the shots in European healthcare?
Natsis believes this is a pointer to the future direction of medicines pricing and reimbursement in Europe. ... PME: How do Europe’s healthcare systems need to evolve? EFPIA:Our current system means the costs are borne in year one from the medicines
Latest news
-
NICE unveils long-awaited review of methodologies
This will include how it should deal with uncertainty around clinical and cost effectiveness data for new medicines at launch. ... This review is a critical opportunity to ensure NICE’s methods are fit for the future and suitable for assessing the
-
Unruffled by ‘outlier’ claims, Vertex CEO upbeat on Orkambi breakthrough
cost and value of the drug, which has a list price of £104, 000 ($136, 000) per patient per year. ... to capture the full value of specialist medicines for small populations.
-
Greater Manchester backs move to outcome-based payment
able to access new and innovative medicines as early as possible and delivering better value for money.”. ... Outcome-based pricing could help the NHS get better value from new medicines and help our members better understand how treatments are
-
Vertex an “extreme outlier” in pricing and behaviour, says NHS England
However, Vertex rejected this offer, saying it “fails to adequately reflect the value of our current and future medicines and the number of patients that will be treated with these medicines". ... Other pharmaceutical companies are working
-
NICE rejects Novartis migraine treatment Aimovig
Ahmad adds: “NICE does not consider impact of diseases on broader society when evaluating the cost-effectiveness of medicines. ... We believe this fails to capture the true value of medicines like Aimovig.
More from news
Approximately 2 fully matching, plus 126 partially matching documents found.
Latest Intelligence
-
Risks, reforms and rewards: the evolving Russian healthcare market
In contrast, the value of medicines bought by the commercial or private healthcare sector was 991bn roubles in 2018, up from 948bn the previous year. ... The Russian market is dominated by generic drugs. Only 14.4% of medicines sold in the country in
-
Leading AstraZeneca’s return to growth in Europe
We brought a lot of innovative new medicines to patients there, which involved intensive work in educating healthcare professionals and the government about the value of innovation in pharma.”. ... That means we need to have a discussion around value,
-
The first, my last, my everything
This growing empowerment arguably has its biggest impact in the arena of high-value medicines. ... The patient voice is increasingly being used to influence payers and encourage them to support high-value medicines.
-
The Orkambi blame game
on the cost and value of the drug, which has a list price of £104, 000 ($136, 000) per patient per year. ... is to capture the full value of specialist medicines for small populations.
-
#OrkambiNow?
per patient per year price – comparable to the cost of older and less effective CF medicines such as Pulmozyme. ... New models urgently needed. It’s widely acknowledged that healthcare systems and the industry need to converge around new models,
More from intelligence
Approximately 1 fully matching, plus 45 partially matching documents found.
Latest appointments
-
Redx poaches AstraZeneca senior executive
grow this company into a very excising and meaningful entity that has the potential to create both important new medicines for patients and generate significant value for shareholders.".
-
Sanofi appoints Dr Yong-Jun Liu as head of research
April. In his new role, Dr Liu will be responsible for all of the Paris-based pharmaceutical company's research and will be tasked with delivering innovative and high-value medicines.
-
ABPI Scotland appoints Sandra Auld as director
the access to and use of new and innovative medicines for Scottish patients. . ... The ABPI Scotland team is fully committed to working with all of our stakeholders to support a common understanding and appreciation of the life-saving and life-enhancing
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603
its state-of-the-art nanotechnology to develop high value medicines where a reduced dose and improved drug delivery is needed, to overcome existing efficacy, tolerability and safety profile concerns.
-
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Before rotating into this practice, I spent the first year of the scheme working with OPEN Value, Informatics &Evidence (OPEN VIE), completing a 6-month rotation in market access followed by ... Getting to experience two disciplines within OPEN VIE was a
-
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The inclusion of innovative medicines in the WHO EML is an important step to help patients gain access to effective treatments. ... According to the WHO, more than 150 countries use the EML to guide decisions about which medicines represent the best
-
NHS medicines optimisation milestone
by 2020/21 if the NHS embraces the use of best value biological medicines in a proactive, systematic and safe way’. ... needs to redefine its value proposition and move the focus away from direct medicines costs to demonstrating how savings can be made
-
How will the NHS’s new medicines savings drive affect pharma?
value medicines that can be easily bought over-the-counter, such as antihistamines and sun cream. . ... In conclusion, the need for pharma to prove the value of its products has never been greater.
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- FDA approves Roche’s Actemra COVID-19 trial
- Roche’s Ocrevus boasts positive long-term data in MS
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Low-dose LSD looks safe for Alzheimer’s patients, but will it work?
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
Madmicrobe Studios
MadMicrobe is an award-winning team of animators and science experts creating photo real life-science animation content for the healthcare and...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
